New Cancer Drug Developed In Taiwan Heading For US Clinical Trials

Taiwan's newly developed anti-cancer drug has been approved by the FDA for trials in the United States. The drug is called MPT0E028 and is a histone deacetylase inhibitor. The drug has shown promise in over 60 different human tumor cell lines in Taiwan studies.

Researchers at the National Taiwan University College of Medicine and Taipei Medical University developed the drug, upon receiving funding from pharmaceutical companies. The funds were provided by Formosa Pharmaceuticals under the National research Program for Biopharmaceuticals. MPT0E028 has shown promise in stopping the growth of tumors in a number of different cancers, including colorectal, hepatic, lung, and pancreatic cancer. The drug also had a positive effect on leukemia and lymphoma.

The number of different cancers that the drug affected has encouraged researchers, and pharmaceutical companies believe that there might be various uses for the drug. Researchers found no adverse side effects in animals during the testing process. Researchers believe that the drug will eventually be one of many targeted cancer therapies, which are slowly overtaking chemotherapy as a cancer treatment option.

Cancer has been the leading cause of death in the country of Taiwan since 1982. Cancer is expected to affect more people in the world in the coming years, as the World Health Organization predicts a rise of 57% in the number of people with cancer.